- Data presented at American Society for Clinical Oncology (“ASCO”) Annual meeting in Chicago
- Data obtained from 42 patients treated with chemotherapy (5-flourouracil and irinotecan) plus bevacizumab (Avastin®) enrolled in a Phase 2 clinical trial
- VEGF-C shown to be significantly raised just prior to and at the time of disease progression treatment resistance), while VEGF-D shown to be significantly increased after disease progression.
- Data supports concept of targeting additional VEGF family proteins to improve treatment outcomes
Melbourne, Australia June 7, 2011– Circadian Technologies Limited (ASX: CIR) announced today the presentation of data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago USA associating resistance to Avastin® with increases in plasma VEGF-C and D concentrations.
For further information please download PDF below:
